Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Inhibikase Therapeutics is a clinical-stage biotech focused on developing therapeutics for cardiopulmonary and neurological diseases. Its pipeline includes IKT-001, a prodrug of imatinib for pulmonary arterial hypertension, and risvodetinib for Parkinson’s disease. The company leverages proprietary kinase inhibitor technology, seeks FDA approval via the 505(b)(2) pathway, and collaborates with research institutions, aiming to offer disease-modifying treatments in niche markets.
This description was generated via AI from an annual report. Updated about 1 year ago.